Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Emilio Parodi & Carl O'Donnell  |  June 23, 2020

(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19tocilizumab

Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease

Marilynn Larkin  |  June 23, 2020

NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email….

Filed under:Uncategorized Tagged with:coronavirusCOVID-19respiratoryRheumatic Disease

Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Megan Brooks  |  June 23, 2020

NEW YORK (Reuters Health)—Patients with some inflammatory rheumatic conditions are at higher risk for hospital-diagnosed COVID-19 infection compared with the general population, but it depends on the condition and therapy used to treat it, according to a study from Spain. It’s now clear that older patients and those with some common diseases are at increased…

Filed under:Conditions Tagged with:coronavirusCOVID-19Rheumatic Disease

COVID-19: Most Individuals with Rheumatic Disease Recover

Lara C. Pullen, PhD  |  June 19, 2020

An analysis of data from the COVID-19 Global Rheumatology Alliance registry shows that use of disease-modifying antirheumatic drugs or non-steroidal anti-inflammatory drugs did not increase the risk of hospitalization for COVID-19 patients with rheumatic disease, but steroid use did.

Filed under:Conditions Tagged with:COVID-19COVID-19 Global Rheumatology AllianceDr. Milena GianfrancescoDr. Philip Robinsonpatient outcomes

Dr. Kawasaki

Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

Renée Bacher  |  June 18, 2020

Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

Filed under:Professional TopicsProfiles Tagged with:KawasakiKawasaki diseaseTomisaku Kawasaki

More Evidence Links Pediatric Inflammatory Multisystem Syndrome to SARS-CoV-2

Will Boggs, MD  |  June 18, 2020

NEW YORK (Reuters Health)—Two new reports in JAMA strengthen the link between SARS-CoV-2 infection and pediatric inflammatory multisystem syndrome (PIMS). Pediatricians from several communities have reported children who developed fever and multisystem inflammation during the COVID-19 pandemic. Some children were critically ill and some had characteristics similar to Kawasaki disease or Kawasaki disease shock syndrome….

Filed under:ConditionsPediatric Conditions Tagged with:ChildrenCOVID-19Kawasaki diseasePediatricpediatric inflammatory multisystem syndrome (PIMS)

After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk

Lisa Rapaport  |  June 15, 2020

(Reuters Health)—Patients hospitalized for a hip fracture are less likely to experience a subsequent fracture-related hospitalization if they start anti-osteoporosis medication sooner, a Taiwanese study suggests.1 Researchers examined data on 77,930 patients aged 50 years and older hospitalized for hip fractures, including 9,986 people prescribed anti-osteoporosis medications within one year of the index fracture. Compared…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:drug treatmentFracturesOsteoporosisosteoporosis treatments

The ACR on Air Podcast’s COVID-19 Series

From the College  |  June 15, 2020

In light of the current COVID-19 pandemic, the ACR has dedicated a few episodes of the ACR on Air podcast to the challenges that have arisen, along with information about the available resources and guidance. The first episode in this special series looks at drug shortages surrounding hydroxy­chloroquine (HCQ) and its initial uses to treat…

Filed under:From the CollegePractice Support Tagged with:ACR on Air podcastCOVID-19

Dr. Bernhard Helps Doctors in Underserved Areas Via the MAVEN Project

Carol Patton  |  June 15, 2020

In 2018, Gerson Bernhard, MD, FACP, MACR, received a call from a primary care physician at a rural clinic in Florida who was treating patients with varying degrees of arthritis. One patient’s case was more complex than the others. Dr. Bernhard guided the doctor through the patient’s history, reviewed lab results, referred related studies, expanded…

Filed under:ProfilesRheum After 5 Tagged with:Dr. Gerson BernhardMAVENUnderserved Patients

Ustekinumab for Behçet’s Disease? The Study Results Are In

Vanessa Caceres  |  June 15, 2020

In a multicenter, prospective, open-label study, ustekinumab therapy was effective in treating oral ulcers resistant to colchicine in patients with Behçet’s disease, according to study author David Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology, Sorbonne University, Paris, and fellow researchers.1 Researchers focused on the topic because oral ulcers are often disabling, have…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:Behçet’s diseaseustekinumab

  • « Previous Page
  • 1
  • …
  • 96
  • 97
  • 98
  • 99
  • 100
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences